WallStSmart

Philip Morris International Inc (PM)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Philip Morris International Inc generates 653% more annual revenue ($40.65B vs $5.40B). PM leads profitability with a 27.9% profit margin vs 27.5%. RMD appears more attractively valued with a PEG of 1.39. RMD earns a higher WallStSmart Score of 70/100 (B).

PM

Strong Buy

70

out of 100

Grade: B-

Growth: 6.0Profit: 8.5Value: 9.3Quality: 5.3
Piotroski: 5/9Altman Z: 2.18

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PMUndervalued (+17.9%)

Margin of Safety

+17.9%

Fair Value

$201.54

Current Price

$165.50

$36.04 discount

UndervaluedFair: $201.54Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PM4 strengths · Avg: 9.3/10
Market CapQuality
$255.09B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
32.9%10/10

Strong operational efficiency at 32.9%

Profit MarginProfitability
27.9%9/10

Keeps 28 of every $100 in revenue as profit

Free Cash FlowQuality
$4.26B8/10

Generating 4.3B in free cash flow

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

PM2 concerns · Avg: 3.5/10
PEG RatioValuation
1.864/10

Expensive relative to growth rate

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : PM

The strongest argument for PM centers on Market Cap, Operating Margin, Profit Margin. Profitability is solid with margins at 27.9% and operating margin at 32.9%.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : PM

The primary concerns for PM are PEG Ratio, Return on Equity.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

RMD carries more volatility with a beta of 0.89 — expect wider price swings.

RMD is growing revenue faster at 11.0% — sustainability is the question.

PM generates stronger free cash flow (4.3B), providing more financial flexibility.

Monitor TOBACCO industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PM scores higher overall (70/100 vs 70/100), backed by strong 27.9% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Philip Morris International Inc

CONSUMER DEFENSIVE · TOBACCO · USA

Philip Morris International Inc. (PMI) is a Swiss-American multinational cigarette and tobacco manufacturing company, with products sold in over 180 countries. The most recognized and best selling product of the company is Marlboro.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?